<DOC>
	<DOCNO>NCT01298687</DOCNO>
	<brief_summary>The purpose study compare incremental dose travoprost ophthalmic solution versus day dose TRAVATAN® lower intraocular pressure ( IOP ) patient open-angle glaucoma ( OAG ) ocular hypertension ( OHT ) .</brief_summary>
	<brief_title>Divided Dose TRAVATAN®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients openangle glaucoma ocular hypertension meet follow IOP criterion : 1 . Mean IOP ≥ 24 mmHg least 1 eye , eye qualify 8 AM Day 0 Day 1 ; 2 . Mean IOP ≤ 36 mmHg eye time point Day 0 Day 1 . Must sign inform consent form . Other protocoldefined inclusion criterion may apply . Females childbearing potential pregnant , test positive urine pregnancy test Screening Visit , intend become pregnant study period , breastfeeding , use highly effective birth control measure . Current history ocular inflammation infection either eye within past 3 month . Corneal thickness great 620 µm determine pachymetry either eye . Severe visual field loss . Cup disc ratio great 0.8 either eye . Intraocular surgery within past 6 month either eye . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>divide dose</keyword>
</DOC>